Experimental treatments for acute ischaemic stroke

Lancet

Volumn 369, Issue 9558, 2007, Pages 331-341

  Sacco, Ralph L ^a,b   Chong, Ji Y ^a   Prabhakaran, Shyam ^c   Elkind, Mitchell SV ^a  

^a Surgeons Columbia University ^*  (United States)

^b Columbia University ^*  (United States)

^c RUSH UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ALBUMIN; ALTEPLASE; ANCROD; ANTITHROMBOCYTIC AGENT; ARGATROBAN; ARUNDIC ACID; BATROXOBIN; BETA1A INTERFERON; CAFFEINE DERIVATIVE; CLOMETHIAZOLE; DESMOTEPLASE; EPTIFIBATIDE; FIBRINOGEN RECEPTOR ANTAGONIST; FIBRINOLYTIC AGENT; GAVESTINEL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INTERCELLULAR ADHESION MOLECULE 1 ANTIBODY; MAGNESIUM; PHENYLEPHRINE; PICLOZOTAN; REPINOTAN; SCAVENGER; TACROLIMUS; TENECTEPLASE; TINZAPARIN; TISSUE PLASMINOGEN ACTIVATOR; UNINDEXED DRUG; UROKINASE;

ANTIINFLAMMATORY ACTIVITY; BLOOD CLOT LYSIS; BRAIN HEMORRHAGE; BRAIN PERFUSION; CLINICAL TRIAL; DOPPLER ECHOGRAPHY; DRUG MEGADOSE; DRUG WITHDRAWAL; EMBOLECTOMY; ENDOVASCULAR SURGERY; EXCITOTOXICITY; EXPERIMENTAL STUDY; HUMAN; HYPERGLYCEMIA; HYPERTENSION; HYPOTHERMIA; LOW DRUG DOSE; MEDICAL INSTRUMENTATION; MEDICAL LITERATURE; MONOTHERAPY; NEUROPROTECTION; NUCLEAR MAGNETIC RESONANCE IMAGING; OCCLUSIVE CEREBROVASCULAR DISEASE; PLURIPOTENT STEM CELL; PRIORITY JOURNAL; RECANALIZATION; REVIEW; TRANSIENT ISCHEMIC ATTACK; TREATMENT DURATION;

EID: 33846369402     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(07)60155-X     Document Type: Review

References (113)

1. Gropen T., Gagliano P., Blake C., et al., NYSDOH Stroke Center Designation Project Workgroup. Quality improvement in acute stroke: the New York State Stroke Center Designation Project. Neurology 67 (2006) 88-93
2. Demchuk A., Burgin W., Christou I., et al. Thrombolysis in brain ischemia (TIBI) transcranial doppler flow grades predict clinical severity, early recovery, and mortality in patients treated with intravenous tissue plasminogen activator. Stroke 32 (2001) 89-93
3. Alexandrov A., Burgin W., Demchuk A., et al. Speed of intracranial clot lysis with intravenous tissue plasminogen activator therapy: sonographic classification and short-term improvement. Circulation 103 (2001) 2897-2902
4. Ribo M., Alvarez-Sabin J., Montaner J., et al. Temporal profile of recanalization after intravenous tissue plasminogen activator: selecting patients for rescue reperfusion techniques. Stroke 37 (2006) 1000-1004
5. Ohman E., Kleiman N., Gacioch G., et al. Combined accelerated tissue plasminogen activator and platelet glycoprotein IIb/IIIa integrin receptor blockade with integrilin in acute myocardial infarction. Circulation 95 (1997) 846-854
6. Lee D., Jo K., Kim H., et al. Local intraarterial urokinase thrombolysis of acute ischemic stroke with or without intravenous abciximab: a pilot study. J Vasc Interv Radiol 13 (2002) 769-773
7. Clinicaltrials.gov. Combined approach to lysis utilizing eptifibatide and rt-PA in acute ischemic stroke (CLEAR Stroke) trial (Nov 1, 2006). http://www.clinicaltrials.gov/ct/show/NCT00250991?order=1 (accessed Dec 22, 2006).
8. Sugg R., Pary J., Uchino K., et al. Argatroban tPA stroke study: study design and results in the first treated cohort. Arch Neurol 63 (2006) 1057-1062
9. Stroke center: stroke trials registry. Reperfusion of stroke safety study imaging evaluation-2 (March 1, 2006). http://www.strokecenter.org/trials/TrialDetail.aspx?tid=538 (accessed Dec 22, 2006).
10. Lewandowski C., Frankel M., Tomsick T., et al. Combined intravenous and intraarterial r-TPA versus intraarterial therapy of acute ischemic stroke: emergency management of stroke (EMS) bridging trial. Stroke 30 (1999) 2598-2605
11. IMS Study Investigators. Combined intravenous and intra-arterial recanalization for acute ischemic stroke: the interventional management of stroke study. Stroke 35 (2004) 904-912
12. NINDS rtPA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. New Engl J Med 333 (1995) 1581-1587
13. Hacke W., Kaste M., Fieschi C., et al. Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke: the European Cooperative Acute Stroke Study (ECASS). JAMA 274 (1995) 1017-1025
14. Hacke W., Kaste M., Fieschi C., et al., for the Second European-Australasian Acute Stroke Study Investigators. Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II). Lancet 352 (1998) 1245-1251
15. Clark W., Wissman S., Albers G., et al. Recombinant tissue-type plasminogen activator (alteplase) for ischemic stroke 3 to 5 hours after symptom onset: the ATLANTIS study: a randomized controlled trial. JAMA 282 (1999) 2019-2026
16. Clark W., Albers G., Madden K., et al. The rt-PA (alteplase) 0 to 6 hour acute stroke trial, part A: results of a double-blind, placebo-controlled, multicenter study. Stroke 31 (2000) 811-816
17. The ATLANTIS, ECASS, and NINDS rt-PA Study Group Investigators. Association of outcome with early stroke treatment: pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA stroke trials. Lancet 363 (2004) 768-774
18. Stroke center: stroke trials registry. Third International Stroke Trial (May 14, 2006). http://www.strokecenter.org/trials/TrialDetail.aspx?tid=81 (accessed Dec 22, 2006).
19. Schellinger P., Fiebach J., and Hacke W. Imaging-based decision making in thrombolytic therapy for ischemic stroke: present status. Stroke 34 (2003) 575-583
20. Kidwell C., Alger J., and Saver J. Beyond mismatch: evolving paradigms in imaging the ischemic penumbra with multimodal magnetic resonance imaging. Stroke 34 (2003) 2729-2735
21. Thomalla G., Schwark C., Sobesky J., et al. Outcome and symptomatic bleeding complications of intravenous thrombolysis within 6 hours in MRI-selected stroke patients: comparison of a German multicenter study with the pooled data of ATLANTIS, ECASS, and NINDS tPA trials. Stroke 37 (2006) 852-858
22. Albers G., Thijs V., Wechsler L., et al., DEFUSE Investigators. Magnetic resonance imaging profiles predict clinical response to early reperfusion: the diffusion and perfusion imaging evaluation for understanding stroke evolution (DEFUSE) study. Ann Neurol 60 (2006) 508-517
23. Butcher K., Parsons M., MacGregor L., et al., EPITHET Investigators. Refining the perfusion-diffusion mismatch hypothesis. Stroke 36 (2005) 1153-1159
24. Reddrop C., Moldrich R., Beart P., et al. Vampire bat salivary plasminogen activator (desmoteplase) inhibits tissue-type plasminogen activator-induced potentiation of excitotoxic injury. Stroke 36 (2005) 1241-1341
25. Hacke W., Albers G., Al-Rawi Y., et al. The desmoteplase in acute ischemic stroke trial: A phase II MRI-based 9 hour window acute stroke thrombolysis trial with intravenous desmoteplase. Stroke 36 (2005) 66-73
26. Furlan A., Eyding D., Albers G., et al. Dose escalation of desmoteplase for acute ischemic stroke (DEDAS): evidence of safety and efficacy 3 to 9 hours after stroke onset. Stroke 37 (2006) 1227-1231
27. Stroke center: stroke trials registry. Desmoteplase in acute ischemic stroke-2. Oct 31, 2006. http://www.strokecenter.org/trials/TrialDetail.aspx?tid=515 (accessed Dec 22, 2006).
28. Haley E., Lyden P., Johnston K., et al. A pilot dose escalation safety study of tenecteplase in acute ischemic stroke. Stroke 36 (2005) 607-612
29. Liu M., Counsell C., Zhao X., and Wardlaw J. Fibrinogen depleting agents for acute ischemic stroke. Cochrane Library 2006. Cochrane Database Syst Rev 3 (2003) CD000091
30. Hennerici M., Kay R., Bogousslavsky J., et al., for the ESTAT investigators. Intravenous ancrod for acute ischaemic stroke in the European Stroke Treatment with Ancrod Trial: a randomised controlled trial. Lancet 368 (2006) 1871-1878
31. Francis C., Blinc A., Lee S., and Cox C. Ultrasound accelerates transport of recombinant tissue plasminogen activator into clots. Ultrasound Med Biol 21 (1995) 419-424
32. Daffertshofer M., Gass A., Ringleb P., et al. Transcranial low-frequency ultrasound-mediated thrombolysis in brain ischemia: increased risk of hemorrhage with combined ultrasound and tissue plasminogen activator: results of a phase II clinical trial. Stroke 36 (2005) 1441-1446
33. Alexandrov A., Molina C., Grotta J., et al., for the CLOTBUST Investigators. Ultrasound-enhanced systemic thrombolysis for acute ischemic stroke. N Engl J Med 351 (2004) 2170-2178
34. Dijkmans P., Juffermans L., Musters R., et al. Microbubbles and ultrasound: from diagnosis to therapy. Eur J Echocardiogr 5 (2004) 245-256
35. Molina C., Ribo M., Rubiera M., et al. Microbubble administration accelerates clot lysis during continuous 2-MHz ultrasound monitoring in stroke patients treated with intravenous tissue plasminogen activator. Stroke 37 (2006) 425-429
36. Clinicaltrials.gov. Microbubbles and ultrasound in stroke trial: MUST study (Oct 11, 2005). http://www.clinicaltrials.gov/show/NCT00222040 (accessed Dec 22, 2006).
37. Stroke center: stroke trials registry. Nano-bubbles enhanced CLOTBUST treatment for acute ischemic stroke (Feb 28, 2006). http://www.strokecenter.org/trials/TrialDetail.aspx?tid=694 (accessed Dec 22, 2006).
38. Mahon B., Nesbit G., Barnwell S., et al. North American clinical experience with the EKOS MicroLysUS infusion catheter for the treatment of embolic stroke. AJNR Am J Neuroradiol 24 (2003) 534-538
39. Stroke center: stroke trials registry. Interventional management of stroke study (Jan 25, 2005). http://www.strokecenter.org/trials/TrialDetail.aspx?tid=487 (accessed Dec 22, 2006).
40. Smith W. Safety of mechanical thrombectomy and intravenous tissue plasminogen activator in acute ischemic stroke: results of the multi mechanical embolus removal in cerebral ischemia (MERCI) trial, part I. AJNR Am J Neuroradiol 27 (2006) 1177-1182
41. Smith W., Sung G., Starkman S., et al. Safety and efficacy of mechanical embolectomy in acute ischemic stroke: results of the MERCI trial. Stroke 36 (2005) 1432-1438
42. Clinicaltrials.gov. MR and recanalization of stroke clots using embolectomy (MR RESCUE) (Oct 16, 2006). http://www.clinicaltrials.gov/ct/show/NCT00389467 (accessed Dec 22, 2006).
43. Berlis A., Lutsep H., Barnwell S., et al. Mechanical thrombolysis in acute ischemic stroke with endovascular photoacoustic recanalization. Stroke 35 (2004) 1112-1116
44. Nesbit G., Luh G., Tien R., and Barnwell S. New and future endovascular treatment strategies for acute ischemic stroke. J Vasc Interv Radiol 15 (2004) 103S-110S
45. Chopko B., Kerber C., Wong W., and Georgy B. Transcatheter snare removal of acute middle cerebral artery thromboembolism: technical case report. Neurosurgery 46 (2000) 1529-1531
46. Kerber C., Barr J., Berger R., and Chopko B. Snare retrieval of intracranial thrombus in patients with acute stroke. J Vasc Interv Radiol 13 (2002) 1269-1274
47. Fourie P., and Duncan I. Microsnare-assisted mechanical removal of intraprocedural distal middle cerebral arterial thromboembolism. AJNR Am J Neuroradiol 24 (2003) 630-632
48. Schumacher H., Meyers P., Yavagal D., et al. Endovascular mechanical thrombectomy of an occluded superior division branch of the left MCA for acute cardioembolic stroke. Cardiovasc Intervent Radiol 26 (2003) 305-308
49. Tsai F., Berberian B., Matovich V., Lavin M., and Alfieri K. Percutaneous transluminal angioplasty adjunct to thrombolysis for acute middle cerebral artery rethrombosis. AJNR Am J Neuroradiol 15 (1994) 1823-1829
50. Ueda T., Sakaki S., Nochide I., Kumon Y., Kohno K., and Ohta S. Angioplasty after intra-arterial thrombolysis for acute occlusion of intracranial arteries. Stroke 29 (1998) 2568-2574
51. Ringer A., Qureshi A., Fessler R., Guterman L., and Hopkins L. Angioplasty of intracranial occlusion resistant to thrombolysis in acute ischemic stroke. Neurosurgery 48 (2001) 1282-1288
52. Nakano S., Iseda T., Yoneyama T., Kawano H., and Wakisaka S. Direct percutaneous transluminal angioplasty for acute middle cerebral artery trunk occlusion: an alternative option to intra-arterial thrombolysis. Stroke 33 (2002) 2872-2876
53. Agarwal P., Borden N., Tan W., and Sen S. Rescue angioplasty after failed intra-arterial thrombolysis in acute middle cerebral artery stroke: a case report. Catheter Cardiovasc Interv 62 (2004) 396-400
54. Leonardi-Bee J., Bath P., Phillips S., Sandercock P., and IST Collaborative Group. Blood pressure and clinical outcomes in the International Stroke Trial. Stroke 33 (2002) 1315-1320
55. Rordorf G., Koroshetz W., Ezzeddine M., Segal A., and Buonanno F. A pilot study of drug-induced hypertension for treatment of acute stroke. Neurology 56 (2001) 1210-1213
56. Hillis A., Ulatowski J., Barker P., et al. A pilot randomized trial of induced blood pressure elevation: effects on function and focal perfusion in acute and subacute stroke. Cerebrovasc Dis 16 (2003) 236-246
57. Stroke center: stroke trials registry. Controlling hypertension and hypotension immediately post-stroke trial (Sept 25, 2005). http://www.strokecenter.org/trials/TrialDetail.aspx?tid=486 (accessed Dec 22, 2006).
58. Campbell M., Grotta J., Gomez C., Ozdemir G., and on behalf of the NeuroFlo Investigators. Perfusion augmentation in stroke using controlled aortic obstruction: pilot study results. Stroke 35 (2004) 291
59. Clinicaltrials.gov. Safety and efficacy of NeuroFlo technology in ischemic stroke (SENTIS) (Dec 27, 2006). http://www.clinicaltrials.gov/ct/gui/show/NCT00119717;jsessionid=BE86BEF78B881E3E2624934E7FD094CC?order=1 (accessed Dec 22, 2006).
60. O'Collins V., Macleod M., Donnan G., Horky L., van der Worp B., and Howells D. 1026 experimental treatments in acute stroke. Ann Neurology 59 (2006) 467-477
61. Lees K., Zivin J., Ashwood T., et al., for the Stroke-Acute Ischemic NXY Treatment (SAINT I) Trial Investigators. NXY-059 for acute ischemic stroke. N Engl J Med 354 (2006) 588-600
62. Adams H., Adams R., Del Zoppo G., Goldstein L., Stroke Council of the American Heart Association, and American Stroke Association. Guidelines for the early management of patients with ischemic stroke: 2005 guidelines update: a scientific statement from the Stroke Council of the American Heart Association/American Stroke Association. Stroke 36 (2005) 916-923
63. Mohr J., Orgogozo J., Harrison M., et al. Meta-analysis of oral nimodipine trials in acute ischemic stroke. Cerebrovasc Dis 4 (1994) 197-203
64. Horn J., de Haan R., Vermeulen M., and Limburg M. Very early nimodipine use in stroke (VENUS): a randomized, double-blind, placebo-controlled trial. Stroke 32 (2001) 461-465
65. Davis S., Albers G., Diener H., Lees K., and Norris J (ASSIST Steering Committee). Termination of acute stroke studies involving Selfotel treatment. Lancet 349 (1997) 32
66. Albers G., Goldstein L., Hall D., Lesko L., and for the Aptiganel Acute Stroke Investigators. Aptiganel hydrochloride in acute ischemic stroke: a randomized controlled trial. JAMA 286 (2001) 2673-2682
67. Albers G., Atkinson R., Kelley R., Rosenbaum D., and for the Dextrorphan Study Group. Safety, tolerability, and pharmacokinetics of the N-methyl-D-aspartate antagonist dextrorphan in patients with acute stroke. Stroke 26 (1995) 254-258
68. Sacco R., DeRosa J., Haley Jr. E., et al. Glycine Antagonist in Neuroprotection Americas Investigators. Glycine antagonist in neuroprotection for patients with acute stroke: GAIN Americas: a randomized controlled trial. JAMA 285 (2001) 1719-1728
69. Diener H.-C. Lubeluzole in acute ischemic stroke treatment: lack of efficacy in a large phase III study with an 8-hour window. Stroke 30 (1999) 234
70. Lyden P., Shuaib A., Ng K., et al., CLASS-I/H/T Investigators. Clomethiazole Acute Stroke Study in ischemic stroke (CLASS-I): final results. Stroke 33 (2002) 122-128
71. Intravenous Magnesium Efficacy in Stroke (IMAGES) Study Investigators. Magnesium for acute stroke (Intravenous Magnesium Efficacy in Stroke trial): randomised controlled trial. Lancet 363 (2004) 439-445
72. The field administration of stroke therapy: magnesium phase 3 clinical trial. A NIH-NINDS-sponsored clinical trial to evaluate field initiation of magnesium neuroprotective therapy in acute stroke. http://www.fastmag.info/ (accessed June 30, 2006).
73. Saver J., Kidwell C., Eckstein M., Starkman S., and for the FAST-MAG Pilot Trial Investigators. Prehospital neuroprotective therapy for acute stroke: results of the field administration of stroke therapy-magnesium (FAST-MAG) pilot trial. Stroke 35 (2004) e106-e108
74. Stroke center: stroke trials registry. Piclozotan in patients with Acute Ischemic Stroke and MRI Penumbra. http://www.strokecenter.org/trials/trialDetail.aspx?tid=599 (accessed Dec 22, 2006).
75. Aranowski J., Strong R., Shirzadi A., and Grotta J. Ethanol plus caffeine (caffeinol) for treatment of ischemic stroke: preclinical experience. Stroke 34 (2003) 1242-1245
76. Belayev L., Khoutorova L., Zhang Y., et al. Caffeinol confers cortical but not subcortical neuroprotection after transient focal cerebral ischemia in rats. Brain Res 1008 (2004) 278-283
77. Tirilizad International Steering Committee. Tirilizad mesylate in acute ischemic stroke: a systematic review. Stroke 32 (2000) 2257-2265
78. RANTTAS Investigators. A randomized trial of tirilizad mesylate in patients with acute ischemic stroke. Stroke 27 (1996) 1453-1458
79. Astrazeneca international. Press release: AstraZeneca announces SAINT II trial results showed no efficacy in acute ischaemic stroke (Oct 26, 2006). http://www.astrazeneca.com/pressrelease/5279.aspx (accessed Dec 22, 2006).
80. Enlimomab Acute Stroke Trial Investigators. Use of anti-ICAM-1 therapy in ischemic stroke: results of the enlimomab acute stroke trial. Neurology 547 (2001) 1428-1434
81. Clinicaltrials.gov. Safety study of interferon beta 1a to for acute stroke (Dec 12, 2006). http://clinicaltrials.gov/ct/show/NCT00097318?order=1 (accessed Dec 22, 2006).
82. Qizilbash N., Lewington S., and Lopez-Arrieta J. Corticosteroids for acute ischemic stroke. Cochrane Database Syst Rev 2 (2000) CD000064
83. Clark W., Wechsler L., Sabounjian L., Schwiderski U., and for the Citicoline Stroke Study Group. A phase III randomized efficacy trial of 2000 mg citicoline in acute ischemic stroke patients. Neurology 57 (2001) 1595-1602
84. Warach S., Pettigrew L., Dashe J., et al. Effect of citicoline on ischemic lesions as measured by diffusion-weighted magnetic resonance imaging. Ann Neurol 48 (2000) 713-722
85. Clinicaltrials.gov. ICTUS Study: international citicoline trial on acute stroke (Oct 31, 2006). http://www.clinicaltrials.gov/ct/show/NCT00331890ICTUS (accessed Dec 22, 2006).
86. Grotta J. Combination Therapy Stroke Trial: Recombinant tissue-type plasminogen activator with/without lubeluzole. Cerebrovasc Dis 12 (2001) 258-263
87. Bruno A., Biller J., Adams Jr. H., et al. Acute blood glucose level and outcome from ischemic stroke: trial of ORG 10172 in Acute Stroke Treatment (TOAST) Investigators. Neurology 52 (1999) 280-284
88. Scott J., Robinson G., French J., O'Connell J., Alberti K., and Gray C. Glucose potassium insulin infusions in the treatment of acute stroke patients with mild to moderate hyperglycemia: the glucose insulin in stroke trial (GIST). Stroke 30 (1999) 793-799
89. Stroke center: stroke trials registry. Treatment of hyperglycemia in ischemic stroke (Oct 8, 2006). http://www.strokecenter.org/trials/trialDetail.aspx?tid=686 (accessed Dec 22, 2006).
90. Stroke center: stroke trials registry. Glucose regulation in acute stroke patients trial (Sept 25, 2006). http://www.strokecenter.org/trials/trialDetail.aspx?tid=681 (accessed Dec 22, 2006).
91. Adams Jr. H., Adams R., Brott T., et al., Stroke Council of the American Stroke Association. Guidelines for the early management of patients with ischemic stroke: a scientific statement from the Stroke Council of the American Stroke Association. Stroke 34 (2003) 1056-1083
92. Amarenco P., Labreuche J., Lavallee P., and Touboul P. Statins in stroke prevention and carotid atherosclerosis: systematic review and up-to-date meta-analysis. Stroke 35 (2004) 2902-2909
93. Ballantyne C. Current and future aims of lipid-lowering therapy: changing paradigms and lessons from the Heart Protection Study on standards of efficacy and safety. Am J Cardiol 92 suppl (2003) 3K-9K
94. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebo-controlled trial. Lancet 360 (2002) 7-22
95. The Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Investigators. High-dose atorvastatin after stroke or transient ischemic attack. N Engl J Med 355 (2006) 549-559
96. Gluckman P., Wyatt J., Azzopardi D., et al. Selective head cooling with mild systemic hypothermia after neonatal encephalopathy: multicentre randomised trial. Lancet 365 (2005) 663-670
97. Sironi L., Cimino M., Guerrini U., et al. Treatment with statins after induction of focal ischemia in rats reduces the extent of brain damage. Arterioscler Thromb Vasc Biol 23 (2003) 322-327
98. Chen J., Zhang Z., Li Y., et al. Statins induce angiogenesis, neurogenesis, and synaptogenesis after stroke. Ann Neurol 53 (2003) 743-751
99. Zhang L., Zhang Z., Ding G., et al. Multitargeted effects of statin-enhanced thrombolytic therapy for stroke with recombinant human tissue-type plasminogen activator in the rat. Circulation 29 (2005) 3486-3494
100. Montaner J., Chacon P., Krupinski J., et al. Safety and efficacy of statins in the acute phase of ischemic stroke: the MISTICS trial. Stroke 35 (2004) 293
101. Ginsberg M. Adventures in the pathophysiology of brain ischemia: penumbra, gene expression, neuroprotection: the 2002 Thomas Willis Lecture. Stroke 34 (2003) 214-223
102. Ginsberg M., Hill M., Palesch Y., Ryckborst K., and Tamariz D. The ALIAS pilot trial: a dose-escalation and safety study of albumin therapy for acute ischemic stroke-I: Physiological responses and safety results. Stroke 37 (2006) 2100-2106
103. Palesch Y., Hill M., Ryckborst K., Tamariz D., and Ginsberg M. The ALIAS pilot trial: a dose-escalation and safety study of albumin therapy for acute ischemic stroke-II: neurologic outcome and efficacy analysis. Stroke 37 (2006) 2107-2114
104. Hypothermia After Cardiac Arrest Study Group. Mild therapeutic hypothermia to improve the neurologic outcome after cardiac arrest. N Engl J Med 346 (2002) 549-556
105. Bernard S., Gray T., Buist M., et al. Treatment of comatose survivors of out-of-hospital cardiac arrest with induced hypothermia. N Engl J Med 346 (2002) 557-563
106. Shankaran S., Laptook A., Ehrenkranz R., et al. Whole-body hypothermia for neonates with hypoxic-ischemic encephalopathy. N Engl J Med 353 (2005) 1574-1584
107. Dippel D., van Breda E., van der Worp H., et al., PISA-Investigators. Effect of paracetamol (acetaminophen) and ibuprofen on body temperature in acute ischemic stroke PISA, a phase II double-blind, randomized, placebo-controlled trial [ISRCTN98608690]. BMC Cardiovasc Disord 3 (2003) 2
108. Georgia M., Krieger D., Abou-Chebl A., et al. Cooling for acute ischemic brain damage (COOL AID): a feasibility trial of endovascular cooling. Neurology 63 (2004) 312-317
109. Stroke Therapy Academic Industry Roundtable. Recommendations for standards regarding preclinical neuroprotective and restorative drug development. Stroke 30 (1999) 2752-2758
110. Stroke Therapy Academic Industry Roundtable. Recommendations for clinical trial evaluation of acute stroke therapies. Stroke 32 (2001) 1598-1606
111. Fisher M., and for the Stroke Therapy Academic Industry Roundtable. Recommendations for advancing development of acute stroke therapies. Stroke 34 (2003) 1539-1546
112. Fisher M., Albers G., Donnan G., et al., Stroke Therapy Academic Industry Roundtable IV. Enhancing the development and approval of acute stroke therapies: Stroke Therapy Academic Industry Roundtable. Stroke 36 (2005) 1808-1813
113. Hickenbottom S., and Grotta J. Neuroprotective therapy. Semin Neurol 18 (1998) 485-492